Abstract
Development of potent, selective and orally bioactive dipeptidyl Peptidase IV inhibitors as antihyperglycemic agents is challenging task due to potential side effects are associated with them. It may result from other prolyldipeptidases of DPP-4 include DPP-2, DPP-8 and DPP-9. To resolve the selectivity issue in different DPP enzymes hologram quantitative structure-activity relationship studies were carried out on a series of potent and selective DPP-4 ligands. To measure selectivity between two kinds of enzyme selectivity data of DPP-4 over DPP-2, DPP-8 and DPP-9 were calculated and best HQSAR models were generated with significant correlation coefficients. The statistical results of the three models showed the best prediction and fitness for the selectivity activities. Docking studies were carried out on conformationally rigid 3-azabicyclo [3.1.0] hexane derivatives which suggested the substitution pattern on P1 and P2 fragment. The finally QSAR model, along with the information obtained from contribution maps and docking studies should be useful for the design of novel DPP-4 ligands having improved selectivity without side effects.
Keywords: HQSAR, 3-azabicyclo [3.1.0] hexane derivatives, Fragment based design, Selectivity, DPP-4 inhibitors, Docking.
Letters in Drug Design & Discovery
Title:Fragment Based HQSAR Modeling and Docking Analysis of Conformationally Rigid 3-azabicyclo [3.1.0] Hexane Derivatives to Design Selective DPP-4 Inhibitors
Volume: 11 Issue: 2
Author(s): Manjunath Ghate and Shailesh V. Jain
Affiliation:
Keywords: HQSAR, 3-azabicyclo [3.1.0] hexane derivatives, Fragment based design, Selectivity, DPP-4 inhibitors, Docking.
Abstract: Development of potent, selective and orally bioactive dipeptidyl Peptidase IV inhibitors as antihyperglycemic agents is challenging task due to potential side effects are associated with them. It may result from other prolyldipeptidases of DPP-4 include DPP-2, DPP-8 and DPP-9. To resolve the selectivity issue in different DPP enzymes hologram quantitative structure-activity relationship studies were carried out on a series of potent and selective DPP-4 ligands. To measure selectivity between two kinds of enzyme selectivity data of DPP-4 over DPP-2, DPP-8 and DPP-9 were calculated and best HQSAR models were generated with significant correlation coefficients. The statistical results of the three models showed the best prediction and fitness for the selectivity activities. Docking studies were carried out on conformationally rigid 3-azabicyclo [3.1.0] hexane derivatives which suggested the substitution pattern on P1 and P2 fragment. The finally QSAR model, along with the information obtained from contribution maps and docking studies should be useful for the design of novel DPP-4 ligands having improved selectivity without side effects.
Export Options
About this article
Cite this article as:
Ghate Manjunath and V. Jain Shailesh, Fragment Based HQSAR Modeling and Docking Analysis of Conformationally Rigid 3-azabicyclo [3.1.0] Hexane Derivatives to Design Selective DPP-4 Inhibitors, Letters in Drug Design & Discovery 2014; 11 (2) . https://dx.doi.org/10.2174/15701808113109990051
DOI https://dx.doi.org/10.2174/15701808113109990051 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Alterations in the Peptidergic Regulation of Energy Balance in the Course of Aging
Current Protein & Peptide Science Venoms and Poisonings during the Centuries: A Narrative Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Aldehyde Dehydrogenase-2 Roles in Ischemic Cardiovascular Disease
Current Drug Targets Vitamin D Supplementation in Diabetic Foot Ulcers: A Current Perspective
Current Diabetes Reviews Tumour-Specific Uptake of Anti-Cancer Drugs: The Future is Here
Current Drug Metabolism Diabetic Foot and Exercise Therapy: Step by Step The Role of Rigid Posture and Biomechanics Treatment
Current Diabetes Reviews Gait-Related Strategies for the Prevention of Plantar Ulcer Development in the High Risk Foot
Current Diabetes Reviews The Engaged Role of Tumor Microenvironment in Cancer Metabolism: Focusing on Cancer-Associated Fibroblast and Exosome Mediators
Anti-Cancer Agents in Medicinal Chemistry Backbone-Cyclized Peptides: A Critical Review
Current Topics in Medicinal Chemistry Editorial [Hot Topic: Ion Channels as a Target for Drug Design )Executive Editor: Kwok-Keung Tai)]
Current Pharmaceutical Design Association between Apo B Levels in Mothers and in their Pre-school Age Offspring
Cardiovascular & Hematological Agents in Medicinal Chemistry Natural Cures for Type 1 Diabetes: A Review of Phytochemicals, Biological Actions, and Clinical Potential
Current Medicinal Chemistry A Multicentre Italian Validation Study in Aging Adults with Down Syndrome and Other Forms of Intellectual Disabilities: Dementia Screening Questionnaire for Individuals with Intellectual Disabilities
Current Alzheimer Research Interleukin-10 and Articular Cartilage: Experimental Therapeutical Approaches in Cartilage Disorders
Current Gene Therapy Cell-penetrating Peptide-based Intelligent Liposomal Systems for Enhanced Drug Delivery
Current Pharmaceutical Biotechnology A Fuzzy System Classification Approach for QSAR Modeling of α- Amylase and α-Glucosidase Inhibitors
Current Computer-Aided Drug Design SGLT-2 Inhibition: Novel Therapeutics for Reno-and Cardioprotection in Diabetes Mellitus
Current Diabetes Reviews Role of Signaling Pathways in Mesenchymal Stem Cell Differentiation
Current Stem Cell Research & Therapy Occupational Respiratory Pathology in Russia: Current Trends and Challenges
Current Respiratory Medicine Reviews Selective Modulators of PPAR Activity as New Therapeutic Tools in Metabolic Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets